This article provides a comprehensive resource for researchers and drug development professionals on the independent validation of prognostic signatures based on m6A-related long non-coding RNAs (lncRNAs).
This article provides a comprehensive framework for researchers and bioinformaticians aiming to develop and optimize prognostic models based on m6A-related long non-coding RNAs (lncRNAs).
This article provides a comprehensive guide for researchers and drug development professionals on implementing rigorous false discovery rate (FDR) control in studies of N6-methyladenosine (m6A)-related long non-coding RNA (lncRNA) signatures.
This article provides a comprehensive framework for researchers and drug development professionals to construct and validate prognostic m6A-related lncRNA signatures while rigorously preventing overfitting.
This comprehensive review explores the emerging role of m6A-related long non-coding RNA (lncRNA) signatures as powerful prognostic tools and predictors of immunotherapy efficacy across multiple cancer types.
This article provides a comprehensive benchmark analysis of Recursive Feature Elimination (RFE) against other feature selection methods in drug discovery applications.
This article provides a comprehensive guide to feature selection methods for researchers and professionals in drug development.
Selecting the optimal feature selection technique is critical for developing accurate and generalizable machine learning models in drug discovery.
Multicollinearity among molecular descriptors presents significant challenges for feature selection in QSAR modeling, particularly when using Recursive Feature Elimination (RFE).
This article provides a comprehensive guide for researchers and drug development professionals on implementing a pipeline combining Recursive Feature Elimination (RFE) and the Synthetic Minority Oversampling Technique (SMOTE) to address...